• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Myelin Repair and ENDECE Neural to develop MS treatment

Myelin Repair and ENDECE Neural to develop MS treatment

February 10, 2012
CenterWatch Staff

The Myelin Repair Foundation (MRF), a nonprofit research organization, and ENDECE Neural have formed a partnership to expedite the advancement of myelin regeneration drug candidates for Multiple Sclerosis (MS) patients through pre-clinical studies and into phase I trials.

Through the collaboration, the newly launched MRF Translational Medicine Center will assess the myelin regenerating capabilities of proprietary small molecule compounds from ENDECE Neural in novel MRF MS models for their effectiveness in reversing myelin damage.

"Unlike current MS therapies, which target immune response and inflammation to slow relapses, our drug compounds are promising candidates for remyelination, with the potential to restore muscle control and mobility.  Without remyelination, there can be no cure for MS," said Dr. James Yarger, Ph.D., president of ENDECE Neural. 

"By combining the innovative approach by ENDECE Neural to remyelination and the resources available at the MRF Translational Medicine Center, we can expedite progress toward developing new MS treatments for patients," said Dr. Jay Tung, Ph.D., vice president of drug discovery and research operations at MRF. "We are excited to work with ENDECE Neural since we both share a deep commitment to bringing novel therapeutics to MS patients who simply cannot wait for new cures."

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing